Therapeutic Intranasal DNA Vaccine Against Tuberculosis Shows Promise
Key Highlights
- The vaccine fuses two genes to direct immune responses specifically to the lungs and airways where TB infection occurs.
- Intranasal delivery targets the respiratory mucosa, generating both localized and systemic immune responses.
- In rhesus macaques, the vaccine elicited durable TB-specific immune responses lasting at least six months.
- This approach aims to shorten TB treatment regimens and improve outcomes, especially against drug-tolerant and resistant strains.
- The study highlights the potential of nasal DNA vaccines to enhance respiratory immunity and fight persistent tuberculosis bacteria.



